ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN,China,Sept. 15,2024-- ImmVira announced the latest clinical results for its lead oncolytic virus product,MVR-T3011,via intravesical administration in patients with high-risk BCG-failure non-